Data Provided by Refinitiv. Minimum 15 minutes delayed.

Immunovaccine Demonstrates Protection Against Lethal Anthrax Challenge with Rapid Acting, Single Dose Vaccine

October 21, 2014 at 12:00 AM EDT

All animals receiving a single dose of DepoVax™ formulated anthrax vaccine survive; significant immune response detected as early as 14 days following vaccination

Halifax, Nova Scotia; October 21, 2014 – Immunovaccine Inc. (“Immunovaccine”) (TSX-V: IMV), a clinical stage vaccine and immunotherapy company,  today announced positive results from anthrax challenge studies in non-human primates (monkeys) using an anthrax vaccine formulated with Immunovaccine’s DepoVax™ delivery system. The studies, performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), showed that subjects given a single dose of the DepoVax™-based vaccine were protected against a lethal anthrax challenge.  

The DepoVax™ formulated anthrax vaccine was tested as a single dose in monkeys to determine how quickly neutralizing antibodies can be produced by the vaccine and to test its ability to protect against a lethal dose of the anthrax causing bacterial spores (B. anthracis).  A group of six animals vaccinated with a single dose of the vaccine was protected from anthrax infection.  Four of the five animals in the study’s positive control group receiving BioThrax® were protected as well; however, they were given two doses of the control vaccine.

BioThrax® is the only FDA-licensed vaccine however multiple immunizations are needed to provide the necessary protection against exposure to anthrax. Three doses of intramuscular injections of BioThrax® are indicated at 0, 1, and 6 months, followed by booster injections at 12 and 18 months. There is currently no licensed anthrax vaccine that can provide protection with one dose.   

In all animals immunized with the DepoVax™-based vaccine, antibody titers generally peaked in the first 28 days then persisted until at least day 70, when animals were exposed to the disease agent. In contrast, animals in the control group receiving BioThrax® required a second dose to produce protective neutralizing titers.  

Further studies will be conducted to evaluate the potential of DepoVax™-based vaccines as single dose, rapid protection against anthrax. 

“We previously announced data that demonstrated single dose protection in rabbits and the potential for single dose protection in non-human primates.  Now we report for the first time the protective capability of a single dose of a DepoVax™-based anthrax vaccine in non-human primates. The results produced in two animal models demonstrate the consistent performance of DepoVax™ in producing protective immunity with a single dose which may translate to other infectious disease applications including Ebola,” said Dr. Marc Mansour, Chief Executive Officer of Immunovaccine.

These studies are intended to evaluate Immunovaccine’s DepoVax™ adjuvanting technology and advance the development of next generation bio-defense vaccines. The studies were conducted under NIAID’s preclinical services program vaccine testing contract (HHSN272201200003I/HHSN27200004),

About DepoVax™

DepoVax™ is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness.  The DepoVax™ platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability. 

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer.  The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.  

Connect at

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information.  Forward-looking statements are based on the estimates and opinions of management on the date the statements are made.  However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.  

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



For Immunovaccine:

Marc Mansour, Chief Executive Officer

T: (902) 492-1819   E:


Tim Brons, Vida Strategic Partners (media)

T: (415) 675-7402   E: